VeriSim Life Receives Two Major Accolades in November

What a tremendous quarter it has been for Serra III and SBIC company VeriSIM Life - the leading artificial intelligence (AI)-enabled, unique R&D decisions de-risker for breakthrough drug development.

Within the same week in November, the company announced it had won two major accolades. The company was named “Predictive Analytics Solution of the Year” at the 2023 BioTech Breakthrough Awards on November 9. This is the second year in a row that VeriSIM has received this award in the same category. BioTech Breakthrough is a leading independent marketing intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products, and services around the globe.

On November 14, VeriSIM announced its Founder and CEO, Jo Varshney, has been awarded the Gold Stevie® Award in the healthcare category in the 20th annual Stevie Awards for Women in Business. The Stevie Awards honor the world's top women entrepreneurs, executives, employees, and the organizations they run. This year's Stevie Awards for Women in Business received more than 1,600 nominations by organizations and individuals for consideration across 100 categories.

Jo enthused “I am honored to be chosen as the 2023 recipient of the Gold Stevie Award alongside so many influential women in the healthcare field from all over the world. This award is a testament to each woman who has dedicated their lives to innovation in the healthcare industry.”

We are a firm believer in the team at VeriSIM and their innovative solution for solving complex problems in drug development. Our hat's off to you, Jo! Proud to be your partner in changing the world.

VeriSim Life Partners with Clarivate

VeriSIM Life, the leading artificial intelligence (AI)-enabled, unique R&D decisions de-risker for breakthrough drug development, this week announced a partnership with Clarivate, a global leader in connecting people and organizations to intelligence they can trust.

The partnership will improve pre-clinical success rates by leveraging VeriSim’s AI drug decision engine and R&D drug discovery intelligence platform from Clarivate. VeriSim is a Serra Capital III and Serra III SBIC company.

To view the full article, follow here.

VeriSIM Life Named “Predictive Analytics Solution of the Year” by BioTEch Breakthrough

VeriSIM Life, a Serra portfolio company in Serra III and SBIC, made an exciting announcement the first week of November that they had received the honor of being named “Predictive Analytics Solution of the Year” in this year’s BioTech Breakthrough Awards. Biotech Breakthrough is a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products, and services around the globe.

VeriSIM Life is the leading artificial intelligence (AI)-enabled unique R&D decisions de-risker for breakthrough drug development. "We are honored to receive this award from BioTech Breakthrough,” said Dr. Jo Varshney, CEO of VeriSIM Life. “Being named Predictive Analytics Solution of the Year validates our recent BIOiSIM platform innovations. Technologies like our unique Translational Index™, which synthesizes the potential for clinical success of any drug candidate, enable smarter decisions about how to advance asset programs and ultimately improve the lives of patients in need.”

View the entire article here.

VeriSIM Life, Total Brain to develop drugs for broad range of neurological disorders

VeriSIM Life, a Serra Capital company, announced this week that it was partnering with Total Brain to develop new drugs for the treatment of a wide array of neurological disorders. This collaboration will integrate VerisSIM’s BIOSIM artificial intelligence-enabled drug development decision engine with Total Brain’s mental health and brain performance database to develop new therapies.

“We are excited to partner with Total Brain to combine the power of their high-dimensional data with our drug prediction engine to open new doors for drug discovery specifically addressing neurological conditions — something that has never been explored this way before,” Jo Varshney, PhD, founder and CEO of VeriSIM Life.

VeriSIMlife Secures $15 Million Series A Funding

VeriSIM Life, the leading artificial intelligence (AI)-enabled, unique R&D decisions de-risker for breakthrough drug development, recently announced it has closed its oversubscribed $15 million Series A round. Serra Ventures participated in the round.

VeriSIM is a Serra Capital III and Serra Capital III SBIC portfolio company. VeriSIM Life has developed a sophisticated computational platform that leverages advanced AI and ML techniques to significantly improve drug discovery and development by greatly reducing the time and money it takes to bring a drug to market.

To view the full article, follow here.

Potential of Artificial Intelligence Replacing Animal Testing in the Future with VerisimLife

Animal testing is considered to be one of the worst cruelties towards any animal in this world— over 100 million animals such as mice, frogs, dogs, rabbits, monkeys, cats, and many others are killed in animal experimentation.

However, Start-ups like Verisim Life have started utilizing the power of artificial intelligence and machine learning in biosimulation to replace animal testing in the nearby future. VeriSim Life is a Serra Capital III and Serra III SBIC portfolio company.

To learn more about VeriSim, follow here.